AR037825A1 - Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epiteliales - Google Patents

Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epiteliales

Info

Publication number
AR037825A1
AR037825A1 ARP020104844A ARP020104844A AR037825A1 AR 037825 A1 AR037825 A1 AR 037825A1 AR P020104844 A ARP020104844 A AR P020104844A AR P020104844 A ARP020104844 A AR P020104844A AR 037825 A1 AR037825 A1 AR 037825A1
Authority
AR
Argentina
Prior art keywords
sec
peptides
hpv
ckii
tumors
Prior art date
Application number
ARP020104844A
Other languages
English (en)
Inventor
Rodriguez Ricardo Silva
Soria Alejandro Moro
Savio Alicia Santos
Lopez Luis Javier Gonzalez
Barrios Belkis Gonzalez
Rodriguez Silvio Ernesto Perea
Vispo Nelson Francisco Santiago
Izaguirre Yaquelin Puchades
Acosta Osvaldo Reyes
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR037825A1 publication Critical patent/AR037825A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Péptidos útiles para el tratamiento de tumores de origen epitelial y especialmente los asociados a tipos oncogénicos de Virus Papiloma (VPH). Identificación de péptidos cuya estructura permita el bloqueo del dominio de fosforilación por Caseína Kinasa II (CKII) mediante la interacción directa con dicho sitio. En la presente se muestran once péptidos de estructura cíclica y secuencia aminoácida diferente, los cuales inhiben el sitio de fosforilación por CKII in vitro, producen citotoxicidad en células de carcinoma de cuello uterino humano transformadas por VPH-16 (CaSki) y además incrementan la sensibilidad de dichas células al efecto citostático del Interferón (IFN). La presente se relaciona además con el uso de estos péptidos conjugados o fusionados a otros péptidos y compuestos químicos de penetración intracelular así como con el uso de moléculas miméticas tanto de origen peptídico como de origen químico. Reivindicación 1: Péptidos con capacidad de unión al sitio de fosforilación por Caseína Kinasa II (CKII) caracterizados porque presentan las secuencias: (a) CSVRQGPVQKC (Id. Sec. N° 1); (b) CSSCQNSPALC (Id. Sec. N° 2); (c) CQIPQRTATRC (Id. Sec. N° 3); (d) CAKQRTDPGYC (Id. Sec. N° 4); (e) CWMSPRHLGTC (Id. Sec. N° 5); (f) CRNCTVIQFSC (Id. Sec. N° 6); (g) CHYIAGTVQGC (Id. Sec. N° 7); (h) CPLVSLRDHSC (Id. Sec. N° 8); (i) CKQSYLHHLLC (Id. Sec. N° 9); (j) CFQPLTPLCRC (Id. Sec. N° 10); (k) CQSYHELLLQC (Id. Sec. N° 11); así como cualquier variante homóloga o mimética de los mismos obtenida por vía sintética o recombinante.
ARP020104844A 2001-12-20 2002-12-13 Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epiteliales AR037825A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010309A CU23225A1 (es) 2001-12-20 2001-12-20 PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES

Publications (1)

Publication Number Publication Date
AR037825A1 true AR037825A1 (es) 2004-12-09

Family

ID=40091679

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104844A AR037825A1 (es) 2001-12-20 2002-12-13 Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epiteliales

Country Status (34)

Country Link
US (2) US7374767B2 (es)
EP (2) EP2383282A1 (es)
JP (1) JP4056476B2 (es)
KR (1) KR100642437B1 (es)
CN (1) CN100368431C (es)
AR (1) AR037825A1 (es)
AT (1) ATE520704T1 (es)
AU (1) AU2002361922B2 (es)
BR (1) BRPI0215213C1 (es)
CA (1) CA2471110C (es)
CR (1) CR7361A (es)
CU (1) CU23225A1 (es)
DK (1) DK1491553T3 (es)
DO (1) DOP2002000548A (es)
ES (1) ES2371239T3 (es)
HK (1) HK1068901A1 (es)
HN (1) HN2002000377A (es)
HR (1) HRP20040663B1 (es)
IL (2) IL162633A0 (es)
IS (1) IS2906B (es)
MA (1) MA27868A1 (es)
MX (1) MXPA04005832A (es)
MY (1) MY133530A (es)
NO (1) NO333259B1 (es)
NZ (1) NZ534170A (es)
PE (1) PE20030861A1 (es)
PT (1) PT1491553E (es)
RU (1) RU2290410C2 (es)
SI (1) SI1491553T1 (es)
TN (1) TNSN04114A1 (es)
UA (1) UA81403C2 (es)
UY (1) UY27602A1 (es)
WO (1) WO2003054002A1 (es)
ZA (1) ZA200405514B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
GB2433740A (en) 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB2441131A (en) * 2006-08-24 2008-02-27 Univ Dundee Modulation of binding of CK2a to NDPK
CN100522992C (zh) * 2007-02-12 2009-08-05 中国科学院昆明动物研究所 一种环状小肽ba
EP2133083A4 (en) * 2007-03-27 2012-02-15 Taiko Pharmaceutical Co Ltd THERAPEUTIC FOR SKIN OR MOLECULE INFECTIONS
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
JP2012520085A (ja) * 2009-03-13 2012-09-06 エーゲン、インコーポレイテッド 生物活性ｒｎａの送達のための組成物及び方法
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CU20210058A7 (es) 2021-07-09 2023-02-13 Ct Ingenieria Genetica Biotecnologia Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE902820A1 (en) * 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
CA2077322A1 (en) 1991-09-04 1993-03-05 Allen I. Oliff Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
ATE235509T1 (de) * 1998-06-30 2003-04-15 Deutsches Krebsforsch Peptide zur inhibition von hpv e7 proteinen
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US6641994B2 (en) * 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES

Also Published As

Publication number Publication date
IS7320A (is) 2004-06-16
PE20030861A1 (es) 2003-12-02
EP1491553B1 (en) 2011-08-17
SI1491553T1 (sl) 2011-12-30
DK1491553T3 (da) 2011-12-05
JP2005525090A (ja) 2005-08-25
MY133530A (en) 2007-11-30
AU2002361922B2 (en) 2007-04-05
BR0215213A (pt) 2004-12-07
US20060233742A1 (en) 2006-10-19
CA2471110A1 (en) 2003-07-03
BRPI0215213B1 (pt) 2018-09-11
CN1620464A (zh) 2005-05-25
KR20050002811A (ko) 2005-01-10
MXPA04005832A (es) 2004-09-13
CR7361A (es) 2005-02-18
IS2906B (is) 2014-11-15
DOP2002000548A (es) 2003-06-30
RU2290410C2 (ru) 2006-12-27
JP4056476B2 (ja) 2008-03-05
US7947287B2 (en) 2011-05-24
US20090005294A1 (en) 2009-01-01
HRP20040663B1 (hr) 2013-05-31
EP2383282A1 (en) 2011-11-02
CU23225A1 (es) 2007-08-30
MA27868A1 (fr) 2006-05-02
UY27602A1 (es) 2003-04-30
CA2471110C (en) 2017-01-31
KR100642437B1 (ko) 2006-11-06
PT1491553E (pt) 2011-11-25
WO2003054002A1 (es) 2003-07-03
HN2002000377A (es) 2003-04-10
HRP20040663A2 (en) 2005-08-31
EP1491553A1 (en) 2004-12-29
ES2371239T3 (es) 2011-12-28
NO20043112L (no) 2004-07-20
NO333259B1 (no) 2013-04-22
TNSN04114A1 (en) 2006-06-01
BRPI0215213C1 (pt) 2021-05-25
HK1068901A1 (en) 2005-05-06
ZA200405514B (en) 2005-03-30
AU2002361922A1 (en) 2003-07-09
CN100368431C (zh) 2008-02-13
US7374767B2 (en) 2008-05-20
IL162633A0 (es) 2005-11-20
RU2004122084A (ru) 2005-03-27
UA81403C2 (en) 2008-01-10
IL162633A (en) 2011-02-28
NZ534170A (en) 2006-08-31
ATE520704T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
AR037825A1 (es) Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epiteliales
CY1110941T1 (el) Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας
CY1105866T1 (el) Αναλογα ταμανταρινης και διδεμνινης και μεθοδοι παρασκευης και χρησης αυτων
RU2010116278A (ru) Модифицированная константная область антитела
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
ES2331730T3 (es) Peptidos sinteticos o naturales que unen la proteina fosfatasa 2a, procedimiento de identificacion y usos.
BRPI1010120A2 (pt) composição de surfactante reconstituído melhorada contendo análogos de proteína b do surfactante (sp-b) e proteína c do surfactante ( sp-c)
Borghouts et al. Peptide aptamers: recent developments for cancer therapy
US11510991B2 (en) Polypeptide conjugates for intracellular delivery of stapled peptides
NO20060374L (no) Peptider og peptidomimetiks med immun-modulerende, anti-inflammatorisk og anti-viral aktivitet
WO2018120277A1 (zh) 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
EP3790890A1 (en) Cyclic cell-penetrating peptides with one or more hydrophobic residues
JP2013005804A (ja) ペプチド抗腫瘍薬
ES2526060T3 (es) Péptido y tratamiento para la infección del VIH-1
WO2014119753A4 (ja) マイオスタチン阻害ペプチド
WO2009065982A1 (es) Péptidos con capacidad para unirse a escurfina y aplicaciones
RU2435783C1 (ru) Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний
CY1112340T1 (el) Πεπτιδια για την θεραπευτικη αγωγη καρκινου που συνδεεται με τον ιο ανθρωπινων θηλωματων (hpv) και αλλων επιθηλιακων ογκων
EP4269424A1 (en) Novel antiviral compounds and use thereof
US20090035310A1 (en) Cancer treatment
RU2008152813A (ru) Пептиды с антипролиферативной активностью
RU2020122291A (ru) Слитый белок, включающий белок il-2 и белок cd80, и его применение
RU2021113908A (ru) Пептидные соединения для индукции апоптоза в опухолевой клетке

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee